Chief Medical Officer, Dr. Lionel Marks de Chabris, and Vice President of Global Marketing, Dr. Brian Jahns, further expand the highly qualified ZYUS executive team
SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a company focused on the global development and commercialization of innovative and patient-focused cannabinoid-based formulations and product candidates, has added two experienced leaders to its powerful executive team with the appointment of Lionel Marks de Chabris, MD to the newly created position of Chief Medical Officer, and Brian Jahns, PharmD, to the position of Vice President, Global Marketing.
Dr. Marks de Chabris and Dr. Brian Jahns will work closely with the ZYUS team leading research and innovation, expansion into global markets and the development of innovative cannabinoid and protein-based formulations, helping to further advance ZYUS’ strategy of improving patient outcomes, both here in Canada and around the world.
An expert in chronic pain management and addiction medicine, Dr. Marks de Chabris has been closely involved with the planning and design of research projects and brings 30 years of medical expertise to ZYUS where he will spearhead the company’s research, patient advocacy, education strategies and the development of phyto-therapeutic formulations for the medical market. Prior to joining ZYUS, Dr. Marks de Chabris served as an assistant professor at the Northern Ontario School of Medicine and established one of only three Chronic Pain Management centers in northern Ontario. Dr. Marks de Chabris holds designations from the Canadian Academy of Pain Management, the American Board of Addiction Medicine, and the College of Family Physicians of Canada.
Dr. Brian Jahns brings more than 25 years of biologics development, medical marketing, and education experience to ZYUS. A Doctor of Pharmacy and respected leader in biopharmaceutical communications, with a proven track record of growing businesses, developing new markets, and launching new therapeutics, Brian previously held roles at Newstrike Brands, Hoffmann-La Roche and Trillium Therapeutics.
“ZYUS is dedicated to unlocking the full potential of phyto-therapeutics to manage disease, advance medicine and improve patient quality of life,” said Brent Zettl, ZYUS CEO. “The appointment of Dr. Marks de Chabris and Dr. Brian Jahns will be instrumental in ZYUS’ development and global distribution of best in class plant-made therapeutics.”
About ZYUS Life Sciences Inc.
ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical research and IP development, we intend to deliver high-quality oils, gel-caps, topical creams and other cannabinoid-based therapeutics and product candidates to patients worldwide. The ZYUS vision is to elevate cannabinoids as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives. ZYUS: Advancing the Science of Well-Being. Visit www.zyus.com.
This news release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to expectations with respect to our business plans and product lines.
Often, but not always, forward-looking statements can be identified by the use of words such as “expects,” “expected,” “expectation,” “anticipates,” “believes,” “intends,” “estimates,” “predicts,” “continues,” “potential,” “targeted,” “plans,” “possible” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” “would” or “should” occur or be achieved, or the negative of these terms or other comparable terminology. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.
Actual results could differ materially from those currently anticipated due to a number of factors and risks. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
ZYUS Media Inquiries
ZYUS Investor Relations
Bruce M. Mann